Matt makes a post....sorta looks good to me...what do you think?
Question: Matt Schissler Would CBAI employ a plan to keep the CCEL deal afloat, reduce future company purchases, and eliminate debt? This would allow CBAI to reward current investors while increasing the stock price to attract the institutions.
ANS: Xannd - must say you get the gold star for most thoughtful questions. Thank you.
However, our competitors read this stuff, everyday. I know this for fact. So I can't tip our hand on future deals, strategy etc. I'll comment though on 30,000 foot view strategy, and you can deduce what you wish. First, we have been and continue to reduce debt. Debt allows us to buy assets. We add debt with a new purchase, then reduce it. At some point, those accumulated assets are cash flow positive, and have a much higher value than when we bought them. That's when everyone wins. As for the future, it's an opportunistic point in stem cell history. We are focused on Asset acquisition at a cost less than the true asset value. Think buy each at $300 and put value at $1000-$2300. Thats a big win for the everyone. The scenarios are endless for CBAI. And because the scenarios are endless, so is the banter, predictions, theories and conversations. I can't immerse myself in them, as much as I'd like to.I've been clear and remain steadfast:
Grow organically to entrench the business, acquire these assets, diversify the revenue streams and get cash flow positive. That's our focus.
AI
